Summit Therapeutics Inc (SMMT) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering SMMT.
|Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
SMMT Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- The number of analysts covering the stock of SMMT is greater than just about none of of all US stocks.
- Summit Therapeutics Inc's variance in analysts' estimates is lower than almost 100% of all US stocks.
- The average analyst price target of SMMT is higher than 7.47% of all US stocks.
- Summit Therapeutics Inc's upside potential (average analyst target price relative to current price) is greater than 16.38% of Pharmaceutical Products stocks.
- SMMT has a lower percent of analysts bearish on the stock than almost 100% of all US stocks.
- SMMT has a greater percentage of analysts bullish on the stock than just about none of of all US stocks.
- Summit Therapeutics Inc's change in bullishness amongst analysts is lower than almost 100% of all US stocks.
Make investment decisions regarding SMMT using the data that counts. Try POWR Ratings for free.